obesity

Pfizer beats Q1 2026 expectations with $0.75 EPS and $14.45B in sales. Patent settlement extends Vyndamax protection to June 2031, ensuring revenue stability.

Global sleep apnea devices market expected to grow 7.05% annually through 2034, driven by rising prevalence and technological advances in CPAP and BiPAP devices.

Boehringer's survodutide shows 16.6% weight loss in Phase 3 trial, benefiting Zealand Pharma with EUR 315M in potential milestone payments and ongoing royalties.

Boehringer Ingelheim's survodutide achieved 16.6% average weight loss in Phase III trials, with 85.1% of patients hitting ≥5% reduction targets, supporting obesity and MASH treatment potential.

Novo Nordisk partners with OpenAI to accelerate drug discovery via AI. Long-term benefits possible, but near-term headwinds from competition and clinical setbacks persist.

Viking Therapeutics will report Q1 2026 earnings April 29 after market close, showcasing progress on obesity and metabolic disorder treatments.

BioAge's BGE-102 achieves best-in-class hsCRP reductions of ≥85% in Phase 1, with excellent tolerability. Phase 2 cardiovascular and diabetic macular edema trials planned for mid-2026.

American Heart Association launches Cardiovascular-Kidney-Metabolic initiative to address interconnected diseases affecting 90% of U.S. adults, emphasizing screening and prevention.

Zealand Pharma opens Cambridge research hub in September 2026 to expand AI-driven drug discovery and develop next-generation hybrid molecule therapeutics.

Embecta to acquire UK firm Owen Mumford for up to $200M, bolstering drug-delivery capabilities and chronic care market reach. Stock rises 4.63%.

Biomea Fusion presents positive Phase II data for icovamenib in type 2 diabetes, showing durable 1.2% HbA1c reduction nine months after dosing with favorable safety profile.

Cadrenal's 12-LOX inhibitor CAD-1005 shows preclinical promise for obesity and diabetes inflammation reduction, potentially complementing GLP-1 medications.

Zealand Pharma reports positive Phase 2 data for petrelintide, achieving 10.7% weight loss versus 1.7% placebo with favorable safety profile.

Roche's petrelintide demonstrates 10.7% weight reduction in Phase II, positioning the amylin analog as a potential alternative to dominant GLP-1 drugs with favorable tolerability. Phase III trials planned.

Global anti-snoring devices market projected to nearly double to $3.36 billion by 2033, driven by obesity, health awareness, and technological advances.